These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1394802)

  • 1. Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin.
    Damia G; Tagliabue G; Zucchetti M; Davoli E; Sessa C; Cavalli F; D'Incalci M
    Cancer Chemother Pharmacol; 1992; 30(6):459-64. PubMed ID: 1394802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin.
    Ferrari A; Damia G; Erba E; Rossi C; Mandelli R; D'Incalci M
    Int J Cancer; 1989 Jun; 43(6):1091-7. PubMed ID: 2659542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent effectiveness of ADM and multiple cycles of DDP on a murine reticulum sarcoma.
    Leonetti C; Zupi G; Calabresi F; Greco C
    Anticancer Res; 1990; 10(1):45-8. PubMed ID: 2185688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo.
    Chen G; Zeller WJ
    Cancer Chemother Pharmacol; 1990; 26(1):37-41. PubMed ID: 2322989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells.
    Katz EJ; Andrews PA; Howell SB
    Cancer Commun; 1990; 2(4):159-64. PubMed ID: 2114928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G; Zeller WJ
    Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and clinical pharmacological evaluation of aphidicolin glycinate.
    Sessa C; Zucchetti M; Davoli E; Califano R; Cavalli F; Frustaci S; Gumbrell L; Sulkes A; Winograd B; D'Incalci M
    J Natl Cancer Inst; 1991 Aug; 83(16):1160-4. PubMed ID: 1886148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Enhancement of antitumor effect of cisplatin on human ovarian cancer by cyclosporin A in vitro and in vivo].
    Zhou Y; Chen H; Yang Q
    Zhonghua Fu Chan Ke Za Zhi; 1996 Jan; 31(1):25-8. PubMed ID: 8758815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
    McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
    Br J Cancer; 1994 Sep; 70(3):449-52. PubMed ID: 8080729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin combined with the new cisplatin-procaine complex DPR: in vitro and in vivo studies.
    Viale M; Vannozzi MO; Merlo F; Cafaggi S; Parodi B; Esposito M
    Eur J Cancer; 1996 Dec; 32A(13):2327-33. PubMed ID: 9038617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells.
    Levasseur LM; Greco WR; Rustum YM; Slocum HK
    Cancer Chemother Pharmacol; 1997; 40(6):495-505. PubMed ID: 9332464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
    Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
    Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin.
    Chen G; Zeller WJ
    Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of sensitivity to cisplatin by orobol is associated with increased mitochondrial cytochrome c release in human ovarian carcinoma cells.
    Isonishi S; Saitou M; Yasuda M; Ochiai K; Tanaka T
    Gynecol Oncol; 2003 Aug; 90(2):413-20. PubMed ID: 12893210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
    Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
    Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian carcinoma biological nanotherapy: Comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery.
    Zhang Y; Zhang P; Zhu T
    Biomed Pharmacother; 2019 Jan; 109():475-483. PubMed ID: 30399584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
    Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
    Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.